Newest Biotech Companies — 2026

Browse the newest privately-funded Biotech companies. Sorted by filing date, with the most recent on top.

About Biotech

Biotech private-company Form D filings span therapeutics (small molecules, biologics, cell and gene therapy), diagnostics, research tools, and contract research organizations. This sector excludes healthcare software and devices. Biotech round sizes are among the largest in the corpus — Series A typically clears $30M, Series B $50M+, crossover rounds leading into IPO can exceed $200M. The sector uses Delaware C-corporation structure almost exclusively. Rule 506(b) is standard. Investor bases skew toward specialized life-science funds (Third Rock, Arch, Flagship, RA Capital), strategic pharma corporate venture, and sovereign-wealth life-science arms. This sector hub lists the most recent biotech Form D filings from SEC EDGAR, updated daily — useful for licensing research, investor benchmarking, and competitive intelligence on emerging therapeutic franchises.

In 2026, Biotech accounts for 70 catalogued filings totaling $956.6M, running at roughly 15.2 filings per week over the last 30 days.

Total raised
$956.6M
Median offering
$4M
Active states
10
Last 30 days
65

Featured Biotech companies in 2026

$142M

NGM Bio Holdings, Inc.

SOUTH SAN FRANCISCO, CA · Filed Mar 27, 2026

NGM Bio Holdings, Inc. is a Biotech company based in SOUTH SAN FRANCISCO, CA. The company is a Corporation, incorporated in Delaware, with i…

$116.7M

Rakuten Medical, Inc.

San Diego, CA · Filed Apr 13, 2026

Rakuten Medical, Inc. is a Biotech company based in San Diego, CA. The company is a Corporation, incorporated in Delaware, with its office a…

$108.6M

Terremoto Biosciences, Inc.

SOUTH SAN FRANCISCO, CA · Filed Apr 22, 2026

Terremoto Biosciences, Inc. is a Biotech company based in SOUTH SAN FRANCISCO, CA. The company is a Corporation, incorporated in Delaware, w…

About Biotech private companies

Biotech Form Ds reflect distinctive capital intensity and regulatory structure. Pre-clinical companies often carry 10+ full-time employees and burn $5M–$15M annually without revenue; IND-stage companies may burn $30M+/year. Rounds are sized to fund specific pre-clinical, IND-enabling, or clinical-trial milestones — Series A might fund IND filing, Series B through Phase 1, and a crossover through initial Phase 2 data. The FDA clinical-trial pathway creates predictable value inflection points that map directly to capital needs. Tranched financings are common: Form D filings may show a large total offering amount with a smaller sold amount when subsequent tranches haven't yet closed. Investor counts stay small (often under 20), reflecting institutional concentration in life-science rounds.

RLL, LLC

Biotech MD
Amount undisclosed

Biotech funding trends

Recent biotech Form D filings cluster around several themes. First, obesity and cardio-metabolic franchises (GLP-1-adjacent, novel incretin agonists, next-generation obesity molecules) continue to attract outsized Series A and B rounds, often $75M+. Second, AI-enabled drug discovery platforms (generative chemistry, protein design, target ID) draw crossover-style rounds but are increasingly distinguished by whether they have true pipeline assets versus platform-only positioning. Third, cell and gene therapy has contracted somewhat post-2023 as clinical setbacks hit the category, showing up as smaller bridge rounds. Fourth, radiopharmaceuticals have emerged as a hot biotech sub-segment — filings occur alongside licensing deals and academic spinouts. Watch for biotech Form Ds with round-number offering amounts ($100M, $250M) — these are often milestone-triggered clinical-trial-financed rounds.